⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14306757 | 1.00 | — | — | |
| SCHEMBL8154035 | 1.00 | — | — | |
| SCHEMBL16454939 | 0.80 | ANPEP (0.33) | — | |
| SCHEMBL20978336 | 0.78 | — | — | |
| SCHEMBL14260134 | 0.78 | — | — | |
| SCHEMBL24060748 | 0.76 | ALDH1A1 (0.43) | — | |
| SCHEMBL15314084 | 0.76 | — | — | |
| SCHEMBL14361058 | 0.76 | — | — | |
| SCHEMBL21690499 | 0.76 | TDP1 (0.35) | — | |
| SCHEMBL16327591 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487570-B2 | Glucagon like peptide analogs, composition, and method of use | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-11-08 | — | — | US | disclosed |
| WO-2012021704-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2011127350-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011091417-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20110172193-A1 | PRO-DRUGS OF (E)-7-(3-(2-AMINO-1-FLUOROETHYLIDENE)PIPERIDIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-8-METHOXY-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID | JANSSEN PHARMACEUTICA NV (BE) | 2011-07-14 | — | — | US | disclosed |
| WO-2011081918-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011031934-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2010099527-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010096462-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC (US) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010091413-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-7598375-B2 | Method of acylating maytansinol with chiral amino acids | MILLENIUM PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | disclosed |